Buy Manufacturer Progestin Micro Powder Gestodene online
What is Gestodene?
Gestodene is a progestin which is used in combination with the estrogen ethinylestradiol as a hormonal contraceptive.
Gestodene Chemical Profile
CAS: 60282-87-3
MF: C21H26O2
MW: 310.43
EINECS: 262-145-8
Chemical Properties White Crystalline Solid
Purity: 99.5%
Usage Orally active gestogen with progesterone-like profile of activity. Used in combination with estrogen as oral contraceptive
Gestodene Certificate Of Analysis
| Test Items |
Specification |
Test Results |
| Description |
White or almost white crystalline powder |
White crystalline powder |
| Melting Point |
191.0~193.0ºC |
192ºC |
| Loss of drying |
≤1.0% |
0.5% |
| Heavy Metal |
≤20ppm |
15ppm |
| TLC |
Only one spot |
Only one spot |
| Assay |
≥99.5% |
99.91% |
| Conclusion |
It complies with the USP 32. |
Gestodene Application
The main use for gestodene is as an oral contraceptive. It mimics the naturally occurring female sex hormone progesterone, which is partially responsible for regulating the menstrual cycle. In order to be effective as a contraceptive,a synthetic version of the other female sex hormone,estrogen, is combined with gestodene.
Gestodene Effects:
Gestodene is androgenically neutral, meaning that contraceptive pills containing gestodene do not exhibit the androgenic side effects (e.g. acne, hirsutism, weight gain) often associated with second-generation contraceptive pills, such as those containing levonorgestrel.
The synthetic estrogen dosage in third-generation contraceptive pills (including those containing gestodene) is lower than that in second-generation oral contraceptives, reducing the likelihood of weight gain, breast tenderness and migraine. Third-generation oral contraceptives are also suitable for use in patients with diabetes or lipid disorders because they have minimal impact on blood glucose levels and the lipid profile.
Gestodene Side effects
Women who take oral contraceptives containing gestodene are 5.6 times as likely to develop venous thromboembolism than women who do not take any contraceptive pill, and 1.6 times as likely to develop venous thromboembolism compared to women taking oral contraceptives containing levonorgestrel.
